Phase
Condition
Cancer/tumors
Platelet Disorders
Bone Diseases
Treatment
Detection of monoclonal component
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patient with Multiple Myeloma
- Patient starting new treatment line, whatever the line is, but with at least 3induction cycles
- Urine monoclonal component ≥ 200mg/24h
Exclusion
Exclusion Criteria:
-Patients with an emergency planned dexamethasone block administration before the firstchemotherapy cycle initiation
Study Design
Study Description
Connect with a study center
Ch Annecy Genevois
Annecy,
FranceActive - Recruiting
Centre Hospitalier William Morey
Chalon Sur Saone,
FranceSite Not Available
Centre Hospitalier Métropole de Savoie
Chambéry,
FranceActive - Recruiting
CHU François Mitterand
Dijon,
FranceActive - Recruiting
CH de Dunkerque
Dunkerque,
FranceSite Not Available
CHD Vendée
La Roche Sur Yon,
FranceActive - Recruiting
Hopital Bicètre
Le Kremlin Bicètre,
FranceActive - Recruiting
Ch Le Mans
Le Mans,
FranceActive - Recruiting
CH de Lens
Lens,
FranceActive - Recruiting
Hopital Claude Huriez-CHRU LILLE
Lille,
FranceSite Not Available
Centre Hospitalier Lyon sud
Lyon,
FranceActive - Recruiting
CHU de Montpellier
Montpellier,
FranceActive - Recruiting
CHU saint Eloi
Montpellier,
FranceSite Not Available
Hôpital E. MULLER
Mulhouse,
FranceActive - Recruiting
CHRU Nantes
Nantes,
FranceActive - Recruiting
CHU Poitiers
Poitiers,
FranceSite Not Available
CHU de Reims
Reims,
FranceSite Not Available
Chu Pontchaillou
Rennes,
FranceSite Not Available
CHU Toulouse
Toulouse,
FranceActive - Recruiting
CHRU Bretonneau
Tours,
FranceActive - Recruiting
CH Bretagne Atlantique Vannes et Auray-P.Chubert
Vannes,
FranceActive - Recruiting
CH de Versailles
Versailles,
FranceSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.